Primary Hyperparathyroidism
Conditions
Keywords
Primary hyperparathyroidism, Parathyroid
Brief summary
Primary hyperparathyroidism is a significant medical and public health problem in the world and affects approximately 100,000 new patients in the United States alone. If left untreated this can lead to renal stones, osteoporosis, fatigue, and depression. The best treatment for primary hyperparathyroidism is surgical parathyroidectomy. However surgical parathyroidectomy can be difficult due to the variant location of the parathyroid glands. Up to 5% of patients leave the operating room without surgical cure. Primary hyperparathyroidism is an ideal disease to investigate intraoperative fluorescent imaging. This would allow surgeons to identify the parathyroid glands and resect the suspicious parathyroid glands. Folate receptor (FR) has been found to be over-expressed in parathyroid tissue and not thyroid issues. An ideal surgical treatment would combine FR-specific fluorescent tracers with intraoperative imaging. It is important to note that FR is expressed only in the proximal tubules of the kidneys, activated macrophages, and in the choroidal plexus. Thus, the false positive detection rate is expected to be extremely low. A group well known to us in the Netherlands has completed a pilot study utilizing a folate-FITC conjugate in 12 patients with ovarian cancer. Another group of investigators in Mayo have subsequently performed this study on 20 more patients without any serious adverse events (personal communication). They report excellent sensitivity and specificity with this technique with only grade 1 side effects (allergic reaction). All side effects reversed when the injection was halted. Patients with a history of allergic reactions to insect bites should not participate (fluorescein is derived from the firefly insect, folate is an essential vitamin). A fluorescent contrast agent (folate-FITC or EC17) will be used to determine if it will localize to the primary tumor nodule(s) or mass(es) of patients undergoing parathyroid surgery.
Interventions
DRUGEC17
Sponsors
University of Pennsylvania
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Adult patients over 18 years of age 2. Patients presenting with primary hyperparathyroidism presumed to be resectable on pre-operative assessment 3. Good operative candidate 4. Subject capable of giving informed consent and participating in the process of consent.
Exclusion criteria
1. Pregnant women as determined by urinary or serum beta hCG within 72 hours of surgery 2. Patients with a history of anaphylactic reactions to Folate-FITC or insects 3. Vulnerable patient populations 1. Homeless patients 2. Patients with drug or alcohol dependence 3. Children and neonates 4. Patients unable to participate in the consent process
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The ability of EC17 and the imaging system to detect FRA positive tumors during surgery conducted 2-4 hours post EC-17 administration. | Within two to four hours of injection of EC17 |
Secondary
| Measure | Time frame |
|---|---|
| The number of participants that will have an adverse reaction to EC17 | Day 1-Day 30 |
Countries
United States
Outcome results
None listed